Last checked at 16 Jan 2024 08:15
UBS downgrades AstraZeneca to 'sell'
(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades10,231
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,705.00
Bid:
1,701.00
Ask:
1,701.50
Change:
32.00 (1.91%)
Spread:
0.50 (0.029%)
Open:
1,685.50
High:
1,718.50
Low:
1,673.00
Prev. Close:
1,673.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Amicus shares fall after Fabry drug fails late-stage study
Thu, 20th Dec 2012 15:47
Dec 20 (Reuters) - Amicus Therapeutics Inc lostnearly half of its market value after the company said itsexperimental drug to treat a rare, inherited disorder failed tomeet the main goal of a late-stage study. The company's shares were down 43 percent at $3.28 in earlytrading on Thursday on the Nasdaq. The stock had gained about 85percent up to the close on Wednesday this year. Amicus said on Wednesday that six-month data from the studyshowed that the drug, Amigal, did not significantly cut down theamount of a kind of fat in kidney blood vessels in Fabry diseasepatients, compared to a placebo. Fabry disease is caused by the body's inability to producethe enzyme that helps breaks down fat. Amigal, being developed in partnership with Britishdrugmaker GlaxoSmithKline Plc, is Amicus's most advancedpipeline product. The news prompted at least three analysts to cut their pricetargets on the stock, and cast doubts on chances of the drugproving strong enough to be approved as a stand-alone therapy. Capstone Investments analyst Mayank Gandhi said Amigal data may not be sufficient to convince clinicians to use it as astand-alone therapy, compared to the strong efficacy proven byFabrazyme, the only enzyme replacement therapy for the diseasefrom Sanofi SA's unit Genzyme. Canaccord Genuity analyst Ritu Baral cut her price target onthe stock to $6 from $11. Leerink Swann analyst Joseph Schwartz said probability ofsuccess for Amigal as a stand-alone therapy was 25 percent nowfrom 75 percent earlier. Amicus also said the U.S. Food and Drug Administrationindicated that it will consider the 12-month efficacy and safetydata from the study. "Should we see extremely strong evidence of stabilization offunctional renal endpoints at 12 months, as well as supportiveGL-3 data, there may be a chance Amicus will file for andreceive approval," Canaccord Genuity's Baral said. The companies expect 12-month data from the study in thefirst half of 2013. (Reporting by Vidya P L Nathan; Editing by Sriraj Kalluvila)
More News
16 Jan 2024 07:37
LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows
(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.
Read more15 Jan 2024 08:42
Zantac fallout unfairly weighing on GSK, says Shore Capital
(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.
Read more10 Jan 2024 09:35
LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more10 Jan 2024 08:25
GSK says Nucala gets green light in China for asthma treatment
(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.
Read more10 Jan 2024 07:22
GSK's Nucala gets fresh approval in China
(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.
Read more9 Jan 2024 16:22
London close: Stocks finish red after choppy session
(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.
Read more9 Jan 2024 08:03
TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion
(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.
Read more9 Jan 2024 07:16
GSK buys respiratory drug maker Aiolos for $1bn
(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).
Read more8 Jan 2024 23:39
Pfizer to remain aggressive on obesity market after setback
NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.
Read more8 Jan 2024 23:00
Pfizer to remain aggressive on obesity market after setback
NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.
Read more8 Jan 2024 19:02
Moderna says it hit its 2023 COVID vaccine sales goal
Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.
Read more4 Jan 2024 14:01
UK dividends calendar - next 7 days
| Friday 5 January | |
| British Land Co PLC | dividend payment date |
| Hill & Smith PLC | dividend payment date |
| JD Sports Fashion PLC | dividend payment date |
| JPMorgan Global Growth & Income PLC | dividend payment date |
| Liontrust Asset Management PLC | dividend payment date |
| Lok'n Store Group PLC | dividend payment date |
| Real Estate Credit Investments Ltd | dividend payment date |
| RS Group PLC | dividend payment date |
| Tate & Lyle PLC | dividend payment date |
| Monday 8 January | |
| abrdn Equity Income Trust PLC | dividend payment date |
| Intermediate Capital Group PLC | dividend payment date |
| Tuesday 9 January | |
| no events scheduled | |
| Wednesday 10 January | |
| Assura PLC | dividend payment date |
| Bellway PLC | dividend payment date |
| Fidelity Special Values PLC | dividend payment date |
| LXi REIT PLC | dividend payment date |
| Severn Trent PLC | dividend payment date |
| Volex PLC | dividend payment date |
| Vp PLC | dividend payment date |
| Thursday 11 January | |
| AJ Bell PLC | ex-dividend payment date |
| Ashtead Group PLC | ex-dividend payment date |
| BlackRock Latin American Investment Trust PLC | ex-dividend payment date |
| CMC Markets PLC | dividend payment date |
| dotdigital Group PLC | ex-dividend payment date |
| Ecora Resources PLC | ex-dividend payment date |
| European Assets Trust PLC | ex-dividend payment date |
| Foresight Group Holdings Ltd | ex-dividend payment date |
| GSK PLC | dividend payment date |
| ICG-Longbow Senior Secured UK Property Debt Investments Ltd | ex-dividend payment date |
| JPMorgan Asia Growth & Income PLC | ex-dividend payment date |
| Keystone Positive Change Investment Trust PLC | ex-dividend payment date |
| LondonMetric Property PLC | dividend payment date |
| Murray International Trust PLC | ex-dividend payment date |
| National Grid PLC | dividend payment date |
| Primary Health Properties PLC | ex-dividend payment date |
| Sage Group PLC | ex-dividend payment date |
| Smiths News PLC | ex-dividend payment date |
| SSE PLC | ex-dividend payment date |
| Supermarket Income REIT PLC | ex-dividend payment date |
| TR Property Investment Trust PLC | dividend payment date |
| Walker Crips Group PLC | ex-dividend payment date |
| WH Smith PLC | ex-dividend payment date |
| Worldwide Healthcare Trust PLC | dividend payment date |
| XPS Pensions Group PLC | ex-dividend payment date |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
3 Jan 2024 17:48
London close: Stocks fall amid rising geopolitical concerns
(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.
Read more3 Jan 2024 17:10
Miners, personal goods stocks drag FTSE 100 to two-week low
Burberry slips on rating downgrade
*Read more